Cardiologists Propose Genomic Therapy Evaluation Strategy
Researchers outline a new framework to assess the justification of genomic treatments for common health conditions.
Updated on Oct. 20, 2026 in Life Sciences
Live Poll
Would you choose a permanent genetic treatment over a traditional, reversible medication for a chronic condition?
Two Michigan Medicine cardiologists have proposed a five-question strategy to determine the appropriateness of genomic therapies for common diseases. The framework addresses concerns regarding the high cost and permanence of these medical interventions.
Why it matters
As genomic therapies expand beyond rare disorders, clinicians must weigh the risks of permanent, non-reversible interventions against existing effective treatments. This framework provides a standardized approach to navigate complex safety and economic challenges.
Some current genomic therapies carry list prices exceeding $1 million per patient. Researchers are currently evaluating whether single-dose gene-editing treatments can provide long-lasting reductions in LDL cholesterol levels.
The players
Eric D. Smith
He is a cardiologist at Michigan Medicine who co-authored the new evaluation framework for genomic therapies.
Venkatesh L. Murthy
He is a cardiologist at Michigan Medicine who collaborated on the proposed guidelines for gene therapy usage.
JAMA Internal Medicine
This is a peer-reviewed medical journal that publishes research and perspectives on clinical practice and health policy.
The details
The proposed strategy suggests that clinicians evaluate therapies based on five key questions before initiating treatment, given that many current therapies use viral delivery methods that prevent subsequent dosing. Because these interventions are permanent and target somatic cells, they present unique challenges compared to standard, reversible medical treatments.
Timeline
October 20, 2026: The perspective was published in JAMA Internal Medicine.
The Big Picture
This framework marks a significant shift in medical practice as it moves beyond the FDA regulatory framework for gene therapy approval to address the practical integration of permanent genetic interventions into standard clinical care. By questioning the necessity of gene-editing for common conditions, the proposal challenges the current industry trajectory that favors increasingly expensive, one-time biological interventions.
Patients may eventually see more rigorous clinical evaluation standards before being offered expensive gene-editing procedures. This approach aims to protect individuals from unnecessary permanent interventions while ensuring that long-term safety monitoring is prioritized in their medical plans.
The takeaway
Patients and their families should discuss the permanency and potential long-term unknowns of genomic treatments with their physicians. It is crucial to consider whether existing, reversible treatments might achieve similar health outcomes without the risks associated with gene-editing technology.
Further reading
For more context on medical advancements, explore the United States Life Sciences section.
More information
Read the complete JAMA Internal Medicine perspective article for further details.
Source note: This article includes information reported by News-Medical.
Live Poll
Would you choose a permanent genetic treatment over a traditional, reversible medication for a chronic condition?
